Soleno Therapeutics (NASDAQ:SLNO) Announces Earnings Results

Soleno Therapeutics (NASDAQ:SLNO) released its quarterly earnings data on Wednesday. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16, FiscalAI reports. The company had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million.

Here are the key takeaways from Soleno Therapeutics’ conference call:

• Strong financial launch: Q4 net revenue was $91.7M (FY2025 net revenue $190.4M on <9 months of sales), Soleno reached profitability (FY net income $20.9M), generated $48.7M cash from operations in Q4, and finished the year with ~$506M in cash and marketable securities, providing runway for commercialization and expansion.
• Commercial traction: Since launch there were 1,250 patient start forms (~12.5% of the U.S. addressable market), 859 active patients, 630 unique prescribers, and coverage for >180M lives, with the company targeting ~1,000 additional start forms over the next 9–12 months.
• Safety and retention: Real-world safety so far mirrors clinical expectations; launch-to-date discontinuation related to adverse events is ~12% (total discontinuation ~15%), and management expects a long-term discontinuation rate of 15–20%.
• EU regulatory progress: The MAA for DCCR (VYKAT XR) was validated, Day‑120 questions were answered, Day‑180 questions are expected imminently and a mid‑2026 EMA decision is anticipated; the company is preparing commercialization options for a meaningful EU market.
• Pipeline expansion plans: Soleno plans to file an IND for Glycogen Storage Disease Type I in H1 2026 and initiate a clinical program in late 2026, has orphan designations in US/EU, and is evaluating other rare-disease indications leveraging the same mechanism.

Soleno Therapeutics Trading Up 4.7%

SLNO opened at $41.01 on Thursday. The business has a 50 day simple moving average of $43.01 and a two-hundred day simple moving average of $53.97. Soleno Therapeutics has a one year low of $36.67 and a one year high of $90.32. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of -22.29 and a beta of -3.16. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88.

Analysts Set New Price Targets

Several brokerages have weighed in on SLNO. Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a research note on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Wells Fargo & Company restated an “overweight” rating and set a $114.00 price target (up from $106.00) on shares of Soleno Therapeutics in a research note on Tuesday, January 20th. Wall Street Zen upgraded Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Zacks Research cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Soleno Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.62.

Hedge Funds Weigh In On Soleno Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SLNO. MML Investors Services LLC bought a new position in shares of Soleno Therapeutics in the fourth quarter worth approximately $220,000. HRT Financial LP bought a new stake in shares of Soleno Therapeutics during the fourth quarter valued at approximately $221,000. US Bancorp DE raised its holdings in Soleno Therapeutics by 135.7% in the 3rd quarter. US Bancorp DE now owns 2,277 shares of the company’s stock worth $154,000 after acquiring an additional 1,311 shares during the last quarter. Osaic Holdings Inc. lifted its position in Soleno Therapeutics by 97.7% in the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock valued at $72,000 after acquiring an additional 423 shares in the last quarter. Finally, Orion Porfolio Solutions LLC bought a new stake in shares of Soleno Therapeutics in the 2nd quarter worth $215,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.